<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01142128</url>
  </required_header>
  <id_info>
    <org_study_id>D.9612.L00058</org_study_id>
    <nct_id>NCT01142128</nct_id>
  </id_info>
  <brief_title>Viokase 16, Viokase16 Plus Nexium and Nexium Alone</brief_title>
  <acronym>AZ</acronym>
  <official_title>A Randomized, Single Site, Double Blind, Fixed Dose, Cross Over Study of Viokase 16, Viokase16 Plus Nexium and Nexium Alone in the Reduction of Abdominal Pain in Patients With Chronic Pancreatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our primary hypothesis is that the addition of Nexium to Viokase 16 will decrease the chronic
      abdominal pain in patients with small duct chronic pancreatitis in a superior fashion
      compared to Viokase 16 plus placebo or to Nexium alone. A secondary hypothesis would be an
      increase in quality of life. Our objective is to elucidate the role of Nexium in the control
      of pancreatic pain, quality of life, and narcotic usage alone or when added to Viokase 16.
      Our endpoints are the reduction of abdominal pain, decreased pain medication usage, decreased
      ER visits and decreased hospital admissions for abdominal pain.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Viokase was taken off market during study and remained off over a year.
  </why_stopped>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of Abdominal Pain for Participants Taking Nexium Alone.</measure>
    <time_frame>4 months</time_frame>
    <description>To elucidate the role of Viokase 16 and Nexium in the control of pancreatic pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reduction of Abdominal Pain for Participants Taking Placebo to Nexium</measure>
    <time_frame>4 months</time_frame>
    <description>To elucidate the role of Viokase 16 and Nexium in the control of pancreatic pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reduction of Abdominal Pain in Participants Taking Viokase 16 Plus Nexium</measure>
    <time_frame>4 months</time_frame>
    <description>To elucidate the role of Viokase 16 and Nexium in the control of pancreatic pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reduction of Abdominal Pain in Participants Taking Viokase 16 Plus Placebo.</measure>
    <time_frame>4 months</time_frame>
    <description>To elucidate the role of Viokase 16 and Nexium in the control of pancreatic pain</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Chronic Pancreatitis</condition>
  <arm_group>
    <arm_group_label>Nexium alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nexium alone is given for one month to be compared to a placebo to Nexium, Viokase 16 plus Nexium and Viokase 16 plus a placebo to Nexium</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo to Nexium, alone</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to Nexium is given instead of Nexium for one month. This will be compared to the Nexium alone, Viokase 16 plus Nexium and Viokase 16 plus placebo to Nexium</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Viokase 16 (pancrelipase) + Nexium</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Viokase 16 (pancrelipase) + Nexium capsules are given per day for one month with the addition of esomeprazole magnesium, one 40mg capsule per day for one month.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Viokase 16 + placebo to Nexium</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Viokase 16 is given with a placebo to Nexium for one month to be compared against Viokase 16 plus Nexium, Nexium alone and Placebo to Nexium alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nexium (esomeprazole magnesium)</intervention_name>
    <description>one 40 mg capsule per day for one month</description>
    <arm_group_label>Nexium alone</arm_group_label>
    <other_name>Nexium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to Nexium</intervention_name>
    <description>one capsule per day for one month</description>
    <arm_group_label>Placebo to Nexium, alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Viokase 16 (pancrelipase) + Nexium</intervention_name>
    <description>Viokase 16 (pancrelipase) + Nexium capsules are given per day for one month with the addition of esomeprazole magnesium, one 40mg capsule per day for one month</description>
    <arm_group_label>Viokase 16 (pancrelipase) + Nexium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Viokase 16 + placebo to Nexium</intervention_name>
    <description>Viokase 16 pancrelipase tablets are given per day for one month with one capsule of placebo to esomeprazole magnesium, one per day for one month</description>
    <arm_group_label>Viokase 16 + placebo to Nexium</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and females age 18 to 75 years inclusive. Female subjects of child bearing
             potential or less than two years post-menopausal must use a medically acceptable form
             of birth control or barrier method and have a negative pregnancy test prior to entry
             into study.

          2. History of abdominal pain associated with chronic pancreatitis

          3. Evidence of chronic pancreatitis as manifested by an abnormal secretin test,
             calcification of the pancreas on plain film, an abnormal CT showing a dilated
             pancreatic duct and/or atrophy, an abnormal
             Endoscopicretrogradecholangeopancreatography (ERCP), or diffuse changes on Endoscopic
             Ultrasound (EUS), fecal elastase &gt; 100ug/g stool, or serum trypsinogen &gt; 20ng/ml

        Exclusion Criteria:

          1. Subjects on enzyme therapy within the last 14 days, proton pump inhibitor (PPI)within
             the last 7 days, or octreotide within 48 hours.

          2. Subjects with known hypersensitivity to pork or exogenous or pancreatic enzymes.

          3. Female subjects who are pregnant or lactating

          4. Subject use of enzyme therapy other than that called for in this study

          5. Subject use of therapeutic amounts of antacids or H2 receptor antagonists during the
             course of the study.

          6. Past history of documented steatorrhea by 72 hour fecal fat determination or current
             history consistent with steatorrhea -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Phillip P Toskes, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2010</study_first_submitted>
  <study_first_submitted_qc>June 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2010</study_first_posted>
  <results_first_submitted>October 19, 2012</results_first_submitted>
  <results_first_submitted_qc>February 20, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 21, 2013</results_first_posted>
  <last_update_submitted>February 20, 2013</last_update_submitted>
  <last_update_submitted_qc>February 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
    <mesh_term>Pancreatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esomeprazole</mesh_term>
    <mesh_term>Pancrelipase</mesh_term>
    <mesh_term>Pancreatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The dates of the recruitment period were February 2009 through January 2010. Subjects recruited at the University of Florida and the Shands Hospital. Recruited a total of 12 subjects. Enrollment was slow due to subjects not wanting to come off their medications, this was unanticipated.</recruitment_details>
      <pre_assignment_details>A total of 12 participants were consented to the study, however, 4 participants were never randomized to the study. Prior to randomization, subjects were off all enzymes and proton pump inhibitor's (PPI's) for 14 days.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>All Participants</title>
          <description>Participants received one of four interventions in a randomized crossover design:
Nexium Alone: Nexium alone is given for one month to be compared to a placebo to Nexium, Viokase 16 plus Nexium and Viokase 16 plus a placebo to Nexium
Placebo to Nexium, Alone: Placebo to Nexium is given instead of Nexium for one month. This will be compared to the Nexium alone, Viokase 16 plus Nexium and Viokase 16 plus placebo to Nexium
Viokase 16 Plus Nexium: Viokase 16 is given with Nexium for one month to be compared against Nexium alone, Placebo to Nexium alone and Viokase 16 plus placebo to Nexium
Viokase 16 Plus Placebo to Nexium: Viokase 16 is given with a placebo to Nexium for one month to be compared against Viokase 16 plus Nexium, Nexium alone and Placebo to Nexium alone</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Nexium Alone</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Placebo to Nexium, Alone</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Viokase 16 Plus Nexium</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Viokase 16 Plus Placebo to Nexium</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Nexium Alone</title>
          <description>Nexium alone is given for one month to be compared to a placebo to Nexium, Viokase 16 plus Nexium and Viokase 16 plus a placebo to Nexium</description>
        </group>
        <group group_id="B2">
          <title>Placebo to Nexium, Alone</title>
          <description>Placebo to Nexium is given instead of Nexium for one month. This will be compared to the Nexium alone, Viokase 16 plus Nexium and Viokase 16 plus placebo to Nexium</description>
        </group>
        <group group_id="B3">
          <title>Viokase 16 Plus Nexium</title>
          <description>Viokase 16 is given with Nexium for one month to be compared against Nexium alone, Placebo to Nexium alone and Viokase 16 plus placebo to Nexium</description>
        </group>
        <group group_id="B4">
          <title>Viokase 16 Plus Placebo to Nexium</title>
          <description>Viokase 16 is given with a placebo to Nexium for one month to be compared against Viokase 16 plus Nexium, Nexium alone and Placebo to Nexium alone</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="2"/>
            <count group_id="B4" value="0"/>
            <count group_id="B5" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Reduction of Abdominal Pain for Participants Taking Nexium Alone.</title>
        <description>To elucidate the role of Viokase 16 and Nexium in the control of pancreatic pain</description>
        <time_frame>4 months</time_frame>
        <population>Analysis was not able to be done due to the small sample size.</population>
        <group_list>
          <group group_id="O1">
            <title>Nexium Alone</title>
            <description>Viokase 16 is given with Nexium for one month to be compared against Nexium alone, Placebo to Nexium alone and Viokase 16 plus placebo to Nexium</description>
          </group>
        </group_list>
        <measure>
          <title>Reduction of Abdominal Pain for Participants Taking Nexium Alone.</title>
          <description>To elucidate the role of Viokase 16 and Nexium in the control of pancreatic pain</description>
          <population>Analysis was not able to be done due to the small sample size.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Reduction of Abdominal Pain for Participants Taking Placebo to Nexium</title>
        <description>To elucidate the role of Viokase 16 and Nexium in the control of pancreatic pain</description>
        <time_frame>4 months</time_frame>
        <population>Analysis was not able to be done due to the small sample size.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo to Nexium, Alone</title>
            <description>Viokase 16 is given with Nexium for one month to be compared against Nexium alone, Placebo to Nexium alone and Viokase 16 plus placebo to Nexium</description>
          </group>
        </group_list>
        <measure>
          <title>Reduction of Abdominal Pain for Participants Taking Placebo to Nexium</title>
          <description>To elucidate the role of Viokase 16 and Nexium in the control of pancreatic pain</description>
          <population>Analysis was not able to be done due to the small sample size.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Reduction of Abdominal Pain in Participants Taking Viokase 16 Plus Nexium</title>
        <description>To elucidate the role of Viokase 16 and Nexium in the control of pancreatic pain</description>
        <time_frame>4 months</time_frame>
        <population>Analysis was not able to be done due to the small sample size.</population>
        <group_list>
          <group group_id="O1">
            <title>Viokase 16 Plus Nexium</title>
            <description>Viokase 16 is given with Nexium for one month to be compared against Nexium alone, Placebo to Nexium alone and Viokase 16 plus placebo to Nexium</description>
          </group>
        </group_list>
        <measure>
          <title>Reduction of Abdominal Pain in Participants Taking Viokase 16 Plus Nexium</title>
          <description>To elucidate the role of Viokase 16 and Nexium in the control of pancreatic pain</description>
          <population>Analysis was not able to be done due to the small sample size.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Reduction of Abdominal Pain in Participants Taking Viokase 16 Plus Placebo.</title>
        <description>To elucidate the role of Viokase 16 and Nexium in the control of pancreatic pain</description>
        <time_frame>4 months</time_frame>
        <population>Analysis was not able to be done due to the small sample size.</population>
        <group_list>
          <group group_id="O1">
            <title>Viokase 16 Plus Placebo to Nexium</title>
            <description>Viokase 16 is given with Nexium for one month to be compared against Nexium alone, Placebo to Nexium alone and Viokase 16 plus placebo to Nexium</description>
          </group>
        </group_list>
        <measure>
          <title>Reduction of Abdominal Pain in Participants Taking Viokase 16 Plus Placebo.</title>
          <description>To elucidate the role of Viokase 16 and Nexium in the control of pancreatic pain</description>
          <population>Analysis was not able to be done due to the small sample size.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from 03/02/2009 until 08/15/2010</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Nexium Alone</title>
          <description>Nexium alone is given for one month to be compared to a placebo to Nexium, Viokase 16 plus Nexium and Viokase 16 plus a placebo to Nexium</description>
        </group>
        <group group_id="E2">
          <title>Placebo to Nexium, Alone</title>
          <description>Placebo to Nexium is given instead of Nexium for one month. This will be compared to the Nexium alone, Viokase 16 plus Nexium and Viokase 16 plus placebo to Nexium</description>
        </group>
        <group group_id="E3">
          <title>Viokase 16 Plus Nexium</title>
          <description>Viokase 16 is given with Nexium for one month to be compared against Nexium alone, Placebo to Nexium alone and Viokase 16 plus placebo to Nexium</description>
        </group>
        <group group_id="E4">
          <title>Viokase 16 Plus Placebo to Nexium</title>
          <description>Viokase 16 is given with a placebo to Nexium for one month to be compared against Viokase 16 plus Nexium, Nexium alone and Placebo to Nexium alone</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDra 10.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated Liver Enzymes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Phillip Toskes, M.D.</name_or_title>
      <organization>University of Florida</organization>
      <phone>352-273-9493</phone>
      <email>phillip.toskes@medicine.ufl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

